Treatment advances for glioblastoma

Expert Review of Neurotherapeutics

Volumn 11, Issue 10, 2011, Pages 1343-1345

  Wong, Eric T ^a   Yamaguchi, Nise H ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antiangiogenesis; glioblastoma; immunotherapy; ketogenic diet; tumor treating (electromagnetic) field

Indexed keywords

BEVACIZUMAB; CEDIRANIB; CILENGITIDE; IRINOTECAN; SUNITINIB; TEMOZOLOMIDE; VANDETANIB; VASCULOTROPIN; XL 184;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; GLIOBLASTOMA; HUMAN; KETOGENIC DIET; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS;

EID: 80053552545     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.127     Document Type: Review

References (20)

1. Stupp RA, Hegi ME, Mason WP et al. Efficacy of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized Phase III study: 5-analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009)
2. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J. Natl Compr. Canc. Netw. 9(4), 403-407 (2011)
3. Reardon DA, Turner S, Peters KB et al. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J. Natl Compr. Canc. Netw. 9(4), 414-427 (2011)
4. De Groot JF, Lamborn KR, Chang SM et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium Study. J Clin Oncol. 29(19), 2689-2695 (2011)
5. De Groot JF, Piao Y. Anti-VEGF but not VEGF receptor inhibitor therapy prolongs survival and blocks myeloid cell recruitment to orthotopic glioblastoma. Proc. Am. Assoc. Cancer Res. 51, 553 (2010)
6. Scott BJ, Quant EC, McNamara MB et al. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-Oncol. 12(6), 603-607 (2010)
7. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and pattern of recurrence. Neurology 70(10), 779-787 (2008)
8. Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26(34), 5610-5617 (2008)
9. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005) (Pubitemid 40349502)
10. Cristofanilli M, Budd T, Ellis M et al. Circulating rumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004) (Pubitemid 39095313)
11. Lun M, Lok E, Gautam S, Wu E, Wong ET. The natural history of extracranial metastasis from glioblastoma multiforme. J. Neurooncol. DOI: 10.1007/s11060-011-0575-0578 (2011) (Epub ahead of print)
12. Lehtinen MK, Zappaterra MW, Chen X et al. The cerebrospinal fluid provides a proliferative niche for neural progenitor cells. Neuron 69(5), 893-905 (2011)
13. Locasale JW, Melman T, Song S et al. Metabolomics profiling of patient cerebrospinal fluid identifies signatures of malignant glioma. Neuro-Oncol. (2011) (In press)
14. Lee SX, Wong ET, Swanson KD. Mitosis interference of cancer cells during anaphase by dielectric field from NovoTTF-100A. Neuro-Oncol. (2011) (In press)
15. Kirson ED, Dbaly V, Tovarys F et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc. Natl Acad. Sci. USA 104(24), 10152-10157 (2007) (Pubitemid 47175278)
16. Stupp R, Kanner A, Engelhard H et al. A prospective, randomized, open-label, Phase III clinical of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma. J. Clin. Oncol. 28(18), LBA2007 (2011)
17. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930), 1029-1033 (2009)
18. Zuccoli G, Marcello N, Pisanello A et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab. 7, 33 (2010)
19. Lowenstein PR. Cancer vaccines in glioma: how to balance the challenges of small trials, efficiency, and potential adverse events. J. Clin. Oncol. 28(31), 4670-4673 (2010)
20. FDA approves new medical device for form of brain cancer www.fda.gqov/NewsEvents/Newsroom/PressAnnouncements/ucm251669.htm